Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis

Published:2020-02-14 Issue: Volume:11 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Yang Yi,Jin Gang,Pang Yao,Huang Yijie,Wang Wenhao,Zhang Hongyi,Tuo Guangxin,Wu Peng,Wang Zequan,Zhu Zijiang

Funder

National Natural Science Foundation of China

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference48 articles.

1. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer;Anagnostou;Cancer Discovery,2017

2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N Engl. J. Med.,2015

3. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions;Atkins;Ann. Oncol.,2017

4. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy;Bang;Int. J. Radiat. Oncol. Biol. Phys.,2017

5. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4Foxp3 cell-mediated modulation of CD103 dendritic cells;Beavis;Cancer Immunol. Res.,2018

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS;Expert Opinion on Drug Safety;2024-07-29

2. Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models;OncoImmunology;2024-06-20

3. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis;Cancer Immunology, Immunotherapy;2024-06-04

4. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis;Journal of the Egyptian National Cancer Institute;2024-05-06

5. Prognostic biomarkers in melanoma: a 2023 update from clinical trials in different therapeutic scenarios;Expert Review of Molecular Diagnostics;2024-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3